Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 16/20 | 0.34 |
| ▸ | CA2 | P00918 | 16/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29175400 | 0.96 | NOS3 (0.38) | NOS3NOS1NOS2ALDH1A1CA1 | |
| SCHEMBL3813150 | 0.93 | DNM1 (0.41) | ALDH1A1DNM1TSHR | |
| SCHEMBL941222 | 0.92 | ALDH1A1 (0.38) | NOS3NOS1NOS2ALDH1A1CA1 | |
| SCHEMBL3812312 | 0.92 | DNM1 (0.44) | ALDH1A1DNM1TSHR | |
| SCHEMBL28344983 | 0.92 | DNM1 (0.44) | ALDH1A1DNM1TSHR | |
| SCHEMBL3815930 | 0.92 | DNM1 (0.44) | ALDH1A1DNM1TSHR | |
| SCHEMBL3812372 | 0.92 | DNM1 (0.44) | ALDH1A1DNM1TSHR | |
| SCHEMBL3812373 | 0.92 | DNM1 (0.44) | ALDH1A1DNM1TSHR | |
| SCHEMBL1884255 | 0.92 | DNM1 (0.44) | ALDH1A1DNM1TSHR | |
| SCHEMBL27529876 | 0.91 | DNM1 (0.43) | ALDH1A1DNM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201115-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2023-06-29 | — | — | US | disclosed |
| US-11633354-B2 | Creatine and/or creatinine compositions and related methods | THERMOLIFE INTERNATIONAL, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230062170-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2023-03-02 | — | — | US | disclosed |
| US-11154499-B2 | Creatine and/or creatinine compositions and related methods | THERMOLIFE INTERNATIONAL, LLC (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210251895-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2021-08-19 | — | — | US | disclosed |
| US-20200246262-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC (US) | 2020-08-06 | — | — | US | disclosed |
| WO-2019191338-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20190298667-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246262-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | MB, CKMT1A; CKMT1B, REN | NOS3 3285/4885NOS1 2779/4885NOS2 2173/4885 |
| US-11154499-B2 | Creatine and/or creatinine compositions and related methods | MB, CKMT1A; CKMT1B, REN | NOS3 3285/4885NOS1 2779/4885NOS2 2173/4885 |
| US-20190298667-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | CKMT1A; CKMT1B, REN, ALB | NOS3 3810/4885NOS1 4018/4885NOS2 3880/4885 |
| US-20230201115-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | CKMT1A; CKMT1B, REN, ALB | NOS3 4094/4885NOS1 4060/4885NOS2 3835/4885 |
| US-11633354-B2 | Creatine and/or creatinine compositions and related methods | MB, CKMT1A; CKMT1B, REN | NOS3 3285/4885NOS1 2779/4885NOS2 2173/4885 |
| US-20230062170-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | CKMT1A; CKMT1B, REN, ALB | NOS3 3810/4885NOS1 4018/4885NOS2 3880/4885 |
| US-20210251895-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | MB, CKMT1A; CKMT1B, REN | NOS3 3285/4885NOS1 2779/4885NOS2 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.